Literature DB >> 22644744

Ethnic differences in 25-hydroxyvitamin D levels and response to treatment in CKD.

Iris Sanchez1, Roberto Mangoo-Karim, Jason R Stubbs, George P Yanev, James B Wetmore.   

Abstract

AIM: Nutritional vitamin D [25(OH)D] deficiency is common in patients with chronic kidney disease (CKD). No studies have specifically examined the differences between ethnic groups in response to ergocalciferol ("D2") therapy.
METHODS: A retrospective analysis was performed to evaluate the effectiveness of D2 therapy as recommended by the KDOQI guidelines in 184 Hispanic and Caucasian nondialysis CKD patients.
RESULTS: Low 25(OH)D levels (<75 nmol/L) were found in 89.4 % of Hispanics versus 61.4 % of Caucasians, despite similar degrees of CKD. Treatment per KDOQI guidelines resulted in 85.5 % of treated Hispanics and 66.7 % of treated Caucasians remaining vitamin D-deficient. Although both Hispanics and Caucasians had significant (P < 0.0001) changes in 25(OH)D levels, absolute changes were modest (12.5 ± 2.0 nmol/mL in Hispanics, 20.0 ± 3.5 nmol/L in Caucasians). The increase seen in Caucasians was significantly greater than in Hispanics (P < 0.0001). In multiple logistic regression modeling, Hispanic ethnicity remained independently associated with poorer response to therapy (P = 0.0055), even after adjustment for other factors.
CONCLUSIONS: While both Hispanics and Caucasians demonstrated suboptimal response to the KDOQI-guided vitamin D repletion strategy, Hispanic ethnicity was significantly associated with poorer response. Our findings may have implications for other darker-skinned populations, even in solar-rich environments.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22644744     DOI: 10.1007/s11255-012-0200-6

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  42 in total

1.  Pathogenic mechanisms for parathyroid hyperplasia.

Authors:  A S Dusso; T Sato; M V Arcidiacono; D Alvarez-Hernandez; J Yang; I Gonzalez-Suarez; Y Tominaga; E Slatopolsky
Journal:  Kidney Int Suppl       Date:  2006-07       Impact factor: 10.545

2.  Dietary calcium, vitamin D, and the prevalence of metabolic syndrome in middle-aged and older U.S. women.

Authors:  Simin Liu; Yiqing Song; Earl S Ford; JoAnn E Manson; Julie E Buring; Paul M Ridker
Journal:  Diabetes Care       Date:  2005-12       Impact factor: 19.112

3.  Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease.

Authors:  Anna L Zisman; Marta Hristova; L Tammy Ho; Stuart M Sprague
Journal:  Am J Nephrol       Date:  2007-01-11       Impact factor: 3.754

Review 4.  Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence.

Authors:  Margherita T Cantorna; Brett D Mahon
Journal:  Exp Biol Med (Maywood)       Date:  2004-12

Review 5.  Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system.

Authors:  Margherita T Cantorna; Yan Zhu; Monica Froicu; Anja Wittke
Journal:  Am J Clin Nutr       Date:  2004-12       Impact factor: 7.045

6.  Vitamin D2 is much less effective than vitamin D3 in humans.

Authors:  Laura A G Armas; Bruce W Hollis; Robert P Heaney
Journal:  J Clin Endocrinol Metab       Date:  2004-11       Impact factor: 5.958

Review 7.  Liver metabolism in CRF.

Authors:  Miroslaw J Smogorzewski; Shaul G Massry
Journal:  Am J Kidney Dis       Date:  2003-03       Impact factor: 8.860

8.  Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study.

Authors:  Prakash Chandra; José Nilo G Binongo; Thomas R Ziegler; Lynn E Schlanger; Wenli Wang; James T Someren; Vin Tangpricha
Journal:  Endocr Pract       Date:  2008 Jan-Feb       Impact factor: 3.443

9.  Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD.

Authors:  Ziyad Al-Aly; Rizwan A Qazi; Esther A González; Angelique Zeringue; Kevin J Martin
Journal:  Am J Kidney Dis       Date:  2007-07       Impact factor: 8.860

10.  Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004.

Authors:  Adit A Ginde; Mark C Liu; Carlos A Camargo
Journal:  Arch Intern Med       Date:  2009-03-23
View more
  2 in total

1.  Cholecalciferol v. ergocalciferol for 25-hydroxyvitamin D (25(OH)D) repletion in chronic kidney disease: a randomised clinical trial.

Authors:  James B Wetmore; Cassandra Kimber; Jonathan D Mahnken; Jason R Stubbs
Journal:  Br J Nutr       Date:  2017-01-09       Impact factor: 3.718

2.  Association between serum 25-hydroxyvitamin D and glycated hemoglobin levels in type 2 diabetes patients with chronic kidney disease.

Authors:  Lee Ling Lim; Yong Muh Ng; Pei San Kang; Soo Kun Lim
Journal:  J Diabetes Investig       Date:  2017-06-27       Impact factor: 4.232

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.